Charles, Roch-Philippe (2015). Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement. Current protocols in pharmacology, 69, 14.33.1-14.33.14. Wiley 10.1002/0471141755.ph1433s69
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Charles_ph1433.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (995kB) | Request a copy |
The prognosis from thyroid cancer subtypes in humans covers a spectrum from "cured at almost 90%" to "100% lethal." Invasive and poorly differentiated forms of thyroid cancer are among the most aggressive human cancers, and there are few effective therapeutic options. Genetically engineered mice, based on mutations observed in patients, can accurately recapitulate the human disease and its progression, providing invaluable tools for the preclinical evaluation of novel therapeutic approaches. This overview details models developed to date as well as their uses for identifying novel anticancer agents. © 2015 by John Wiley & Sons, Inc.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine |
UniBE Contributor: |
Charles, Roch-Philippe |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1934-8290 |
Publisher: |
Wiley |
Language: |
English |
Submitter: |
Roch-Philippe Charles |
Date Deposited: |
29 Feb 2016 16:38 |
Last Modified: |
05 Dec 2022 14:52 |
Publisher DOI: |
10.1002/0471141755.ph1433s69 |
PubMed ID: |
26344211 |
Uncontrolled Keywords: |
BRAF mutations; cancer model; genetically engineered mice; papillary and anaplastic thyroid cancer; pre-clinical platform |
BORIS DOI: |
10.7892/boris.76364 |
URI: |
https://boris.unibe.ch/id/eprint/76364 |
Actions (login required)
 |
Edit item |